Legal & General Group
FULC icon

Legal & General Group’s Fulcrum Therapeutics FULC Stock Holding History

Legal & General Group’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$136K Buy
17,704
+1,331
+8% +$12.3K ﹤0.01% 2581
2025
Q4 		$185K Hold
16,373
– – ﹤0.01% 2590
2025
Q3 		$151K Sell
16,373
-1,088
-6% -$7.87K ﹤0.01% 2602
2025
Q2 		$120K Buy
17,461
+12,173
+230% +$65.1K ﹤0.01% 2631
2025
Q1 		$15.2K Sell
5,288
-1,232
-19% -$4.53K ﹤0.01% 3041
2024
Q4 		$30.6K Hold
6,520
– – ﹤0.01% 2880
2024
Q3 		$23.3K Buy
6,520
+520
+9% +$3.86K ﹤0.01% 2992
2024
Q2 		$37.3K Buy
+6,000
New +$45.5K ﹤0.01% 2834
2023
Q2 		– Sell
-9,496
Closed -$27.1K – 3447
2023
Q1 		$27.1K Sell
9,496
-4,429
-32% -$39.7K ﹤0.01% 2985
2022
Q4 		$101K Buy
13,925
+1,066
+8% +$6.95K ﹤0.01% 2814
2022
Q3 		$104K Sell
12,859
-4,460
-26% -$31.9K ﹤0.01% 2810
2022
Q2 		$85K Buy
17,319
+991
+6% +$9.68K ﹤0.01% 2897
2022
Q1 		$385K Sell
16,328
-1,930
-11% -$27.3K ﹤0.01% 2464
2021
Q4 		$323K Buy
18,258
+16,129
+758% +$319K ﹤0.01% 2545
2021
Q3 		$60K Buy
2,129
+364
+21% +$6.9K ﹤0.01% 2933
2021
Q2 		$18K Sell
1,765
-143
-7% -$1.45K ﹤0.01% 3326
2021
Q1 		$22K Buy
1,908
+334
+21% +$4.13K ﹤0.01% 3093
2020
Q4 		$18K Hold
1,574
– – ﹤0.01% 3132
2020
Q3 		$12K Sell
1,574
-470
-23% -$5.66K ﹤0.01% 3154
2020
Q2 		$37K Buy
2,044
+105
+5% +$1.65K ﹤0.01% 2815
2020
Q1 		$25K Buy
1,939
+911
+89% +$14.6K ﹤0.01% 2826
2019
Q4 		$17K Buy
1,028
+152
+17% +$1.45K ﹤0.01% 3219
2019
Q3 		$6K Buy
+876
New +$9.69K ﹤0.01% 3317

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Legal & General Group's FULC Position: Q1 2026 in Review

Legal & General Group increased its Fulcrum Therapeutics (FULC) stake by 8.1% in Q1 2026, buying an estimated $12.3K and bringing the position to 17,704 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #2581.

Legal & General Group first reported a position in FULC in Q3 2019 and has held it in 23 quarters since. The position peaked at $385K in Q1 2022. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Legal & General Group held 17,704 shares of Fulcrum Therapeutics worth $136K as of Q1 2026.
  • Legal & General Group bought 1,331 Fulcrum Therapeutics shares in Q1 2026, an estimated $12.3K.
  • Fulcrum Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2581 holding.
  • Legal & General Group first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 23 quarters since.
  • Legal & General Group's Fulcrum Therapeutics position peaked at $385K in Q1 2022.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.